Trial Profile

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Tagraxofusp (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes
Focus Adverse reactions

24 Nov 2025 According to a Dana-Farber Cancer Institute media release, data from this trial to be presented at ASH American Society of Hematology (ASH) 2025
19 Jun 2025 Planned End Date changed from 31 May 2026 to 31 May 2027.
19 Jun 2025 Planned primary completion date changed from 31 May 2025 to 31 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com